Immunogenicity of a protective intradermal DNA vaccine against lassa virus in cynomolgus macaques

References

• McLay L, Liang Y, Ly H. Comparative analysis of disease pathogenesis and molecular mechanisms of new world and old world arenavirus infections. J Gen Virol. 2014;95:1–15. doi:10.1099/vir.0.054783-0.
   PubMed Web of Science ®Google Scholar
• Center for Disease Control and Prevention. Lassa fever fact sheet; 2018. [Accessed 2018 Dec 07]. https://www.cdc.gov/vhf/lassa/index.html.
   Google Scholar
• Hallam HJ, Hallam S, Rodriguez SE, Barrett ADT, Beasley DWC, Chua A, Ksiazek TG, Milligan GN, Sathiyamoorthy V, Reece LM. Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development. NPJ Vaccines. 2018;3:11. doi:10.1038/s41541-018-0049-5.
   PubMed Web of Science ®Google Scholar
• Amorosa V, MacNeil A, McConnell R, Patel A, Dillon KE, Hamilton K, Erickson BR, Campbell S, Knust B, Cannon D, et al. Imported lassa fever, Pennsylvania, USA, 2010. Emerg Infect Dis. 2010;16:1598–600. doi:10.3201/eid1610.100774.
   PubMed Web of Science ®Google Scholar
• Ehlkes L, George M, Samosny G, Burckhardt F, Vogt M, Bent S, Jahn K, Zanger P. Management of a lassa fever outbreak, Rhineland-Palatinate, Germany, 2016. Euro Surveillance. 2017;22(39). doi: 10.2807/1560-7917.ES.2017.22.39.16-00728.
   Google Scholar
• Iroezindu MO, Unigwe US, Okwara CC, Ozoh GA, Ndu AC, Ohanu ME, Nwoko UO, Okoroafor UW, Ejimudo E, Tobin EA, et al. Lessons learnt from the management of a case of lassa fever and follow-up of nosocomial primary contacts in Nigeria during Ebola virus disease outbreak in West Africa. Trop Med Inter Health TM & IH. 2015;20:1424–30. doi:10.1111/tmi.12565.
   PubMed Web of Science ®Google Scholar
• WHO. Emergencies preparedness, response; 2018. [Accessed 2018 March 10]. http://www.who.int/csr/don/01-march-2018-lassa-fever-nigeria/en/.
   Google Scholar
• Mateer EJ, Huang C, Shehu NY, Paessler S. Lassa fever-induced sensorineural hearing loss: A neglected public health and social burden. PLoS Negl Trop Dis. 2018;12:e0006187. doi:10.1371/journal.pntd.0006187.
   PubMed Web of Science ®Google Scholar
• Carnec X, Mateo M, Page A, Reynard S, Hortion J, Picard C, Yekwa E, Barrot L, Barron S, Vallve A, et al. A vaccine platform against arenaviruses based on a recombinant hyper-attenuated Mopeia virus expressing heterologous glycoproteins. J Virol. 2018. doi:10.1128/JVI.02230-17.
   PubMed Web of Science ®Google Scholar
• Jiang X, Dalebout TJ, Bredenbeek PJ, Carrion R, Jr., Brasky K, Patterson J, Goicochea M, Bryant J, Salvato MS, Lukashevich IS. Yellow fever 17D-vectored vaccines expressing lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs. Vaccine. 2011;29:1248–57. doi:10.1016/j.vaccine.2010.11.079.
   PubMed Web of Science ®Google Scholar
• Safronetz D, Mire C, Rosenke K, Feldmann F, Haddock E, Geisbert T, Feldmann H. A recombinant vesicular stomatitis virus-based lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct lassa viruses. PLoS Negl Trop Dis. 2015;9:e0003736. doi:10.1371/journal.pntd.0003736.
   PubMed Web of Science ®Google Scholar
• Sardesai NY, Weiner DB. Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol. 2011;23:421–29. doi:10.1016/j.coi.2011.03.008.
   PubMed Web of Science ®Google Scholar
• Bagarazzi ML, Yan J, Morrow MP, Shen X, Parker RL, Lee JC, Giffear M, Pankhong P, Khan AS, Broderick KE, et al. Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med. 2012;4:155ra38. doi:10.1126/scitranslmed.3004414.
   Web of Science ®Google Scholar
• Best SR, Peng S, Juang CM, Hung CF, Hannaman D, Saunders JR, Wu TC, Pai SI. Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine. 2009;27:5450–59. doi:10.1016/j.vaccine.2009.07.005.
   PubMed Web of Science ®Google Scholar
• Livingston BD, Little SF, Luxembourg A, Ellefsen B, Hannaman D. Comparative performance of a licensed anthrax vaccine versus electroporation based delivery of a PA encoding DNA vaccine in rhesus macaques. Vaccine. 2010;28:1056–61. doi:10.1016/j.vaccine.2009.10.111.
   PubMed Web of Science ®Google Scholar
• Yin J, Dai A, Lecureux J, Arango T, Kutzler MA, Yan J, Lewis MG, Khan A, Sardesai NY, Montefiore D, et al. High antibody and cellular responses induced to HIV-1 clade C envelope following DNA vaccines delivered by electroporation. Vaccine. 2011;29:6763–70. doi:10.1016/j.vaccine.2010.12.055.
   PubMed Web of Science ®Google Scholar
• Tebas P, Roberts CC, Muthumani K, Reuschel EL, Kudchodkar SB, Zaidi FI, White S, Khan AS, Racine T, Choi H, et al. Safety and immunogenicity of an anti-zika virus DNA vaccine - preliminary report. N Engl J Med. 2017. doi:10.1056/NEJMoa1708120.
   Web of Science ®Google Scholar
• Cashman KA, Broderick KE, Wilkinson ER, Shaia CI, Bell TM, Shurtleff AC, Spik K, Badger C, Guttieri M, Sardesai N, et al. Enhanced efficacy of a codon-optimized DNA vaccine encoding the glycoprotein precursor gene of lassa virus in a guinea pig disease model when delivered by dermal electroporation. Vaccines. 2013;1:262–77. doi:10.3390/vaccines1030262.
   Google Scholar
• Cashman KA, Wilkinson ER, Shaia CI, Facemire PR, Bell TM, Bearss JJ, Shamblin JD, Wollen SE, Broderick KE, Sardesai NY, et al. A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against lassa fever. Hum Vaccin Immunother. 2017;13:2902–11. doi:10.1080/21645515.2017.1356500.
   PubMed Web of Science ®Google Scholar
• Amante DH, Smith TR, Mendoza JM, Schultheis K, McCoy JR, Khan AS, Sardesai NY, Broderick KE. Skin transfection patterns and expression kinetics of electroporation-enhanced plasmid delivery using the CELLECTRA-3P, a portable next-generation dermal electroporation device. Hum Gene Ther Methods. 2015;26:134–46. doi:10.1089/hgtb.2015.020.
   PubMed Web of Science ®Google Scholar
• Smith TR, Schultheis K, Kiosses WB, Amante DH, Mendoza JM, Stone JC, McCoy JR, Sardesai NY, Broderick KE. DNA vaccination strategy targets epidermal dendritic cells, initiating their migration and induction of a host immune response. Mol Ther Methods Clin Dev. 2014;1:14054. doi:10.1038/mtm.2014.54.
   PubMed Web of Science ®Google Scholar
• Hensley LE, Smith MA, Geisbert JB, Fritz EA, Daddario-DiCaprio KM, Larsen T, Geisbert TW. Pathogenesis of lassa fever in cynomolgus macaques. Virol J. 2011;8:205. doi:10.1186/1743-422X-8-205.
   PubMed Web of Science ®Google Scholar
• Cashman KA, Wilkinson ER, Zeng X, Cardile AP, Facemire PR, Bell TM, Bearss JJ, Shaia CI, Schmaljohn CS. Immune-mediated systemic vasculitis as the proposed cause of sudden-onset sensorineural hearing loss following lassa virus exposure in cynomolgus macaques. MBio. 2018;9(5). pii: e01896–18. doi:10.1128/mBio.01896-18.
   Web of Science ®Google Scholar
• Robinson JE, Hastie KM, Cross RW, Yenni RE, Elliott DH, Rouelle JA, Kannadka CB, Smira AA, Garry CE, Bradley BT, et al. Most neutralizing human monoclonal antibodies target novel epitopes requiring both lassa virus glycoprotein subunits. Nat Commun. 2016;7:11544. doi:10.1038/ncomms11544.
   PubMed Web of Science ®Google Scholar
• Fisher-Hoch SP, Hutwagner L, Brown B, McCormick JB. Effective vaccine for lassa fever. J Virol. 2000;74:6777–83. doi:10.1128/jvi.74.15.6777-6783.2000.
   PubMed Web of Science ®Google Scholar
• Bull M, Lee D, Stucky J, Chiu YL, Rubin A, Horton H, McElrath MJ. Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials. J Immunol Methods. 2007;322:57–69. doi:10.1016/j.jim.2007.02.003.
   PubMed Web of Science ®Google Scholar
• Prescott JB, Marzi A, Safronetz D, Robertson SJ, Feldmann H, Best SM. Immunobiology of Ebola and lassa virus infections. Nat Rev Immunol. 2017;17:195–207. doi:10.1038/nri.2016.138.
   PubMed Web of Science ®Google Scholar
• Baize S, Marianneau P, Loth P, Reynard S, Journeaux A, Chevallier M, Tordo N, Deubel V, Contamin H. Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys. J Virol. 2009;83:5890–903. doi:10.1128/JVI.01948-08.
   PubMed Web of Science ®Google Scholar
• Warner BM, Safronetz D, Stein DR. Current research for a vaccine against Lassa hemorrhagic fever virus. Drug Des Devel Ther. 2018;12:2519–27. doi:10.2147/DDDT.S147276.
   PubMed Web of Science ®Google Scholar
• Cross RW, Mire CE, Branco LM, Geisbert JB, Rowland MM, Heinrich ML, Goba A, Momoh M, Grant DS, Fullah M, et al. Treatment of lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies. Antiviral Res. 2016;133:218–22. doi:10.1016/j.antiviral.2016.08.012.
   PubMed Web of Science ®Google Scholar
• Mire CE, Cross RW, Geisbert JB, Borisevich V, Agans KN, Deer DJ, Rowland MM, Goba A, Momoh M, Boisen ML, et al. Human-monoclonal-antibody therapy protects nonhuman primates against advanced lassa fever. Nat Med. 2017;23:1146–49. doi:10.1038/nm.4396.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Jones S, Fritz EA, Shurtleff AC, Geisbert JB, Liebscher R, Grolla A, Ströher U, Fernando L, Daddario KM, et al. Development of a new vaccine for the prevention of lassa fever. PLoS Med. 2005;2:e183. doi:10.1371/journal.pmed.0020183.
   PubMed Web of Science ®Google Scholar
• Lukashevich IS, Carrion R, Jr., Salvato MS, Mansfield K, Brasky K, Zapata J, Cairo C, Goicochea M, Hoosien GE, Ticer A, et al. Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for lassa fever in small non-human primates. Vaccine. 2008;26:5246–54. doi:10.1016/j.vaccine.2008.07.057.
   PubMed Web of Science ®Google Scholar
• Bowen MD, Rollin PE, Ksiazek TG, Hustad HL, Bausch DG, Demby AH, Bajani MD, Peters CJ, Nichol ST. Genetic diversity among lassa virus strains. J Virol. 2000;74:6992–7004. doi:10.1128/jvi.74.15.6992-7004.2000.
   PubMed Web of Science ®Google Scholar
• Andersen KG, Shapiro BJ, Matranga CB, Sealfon R, Lin AE, Moses LM, Folarin OA, Goba A, Odia I, Ehiane PE, et al. Clinical sequencing uncovers origins and evolution of lassa virus. Cell. 2015;162:738–50. doi:10.1016/j.cell.2015.07.020.
   PubMed Web of Science ®Google Scholar